Gene Therapy for Hemoglobinopathy, Sickle Cell Disease by

Source Details

jrose11_11 — 2024-05-22 18:07:48 UTC

Title:

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

Author: U.S. Food & Drug Administration

Published: December 08, 2023

Summary Of Content

jrose11_11 — 2024-05-22 18:08:38 UTC

The FDA has approved two new gene therapies, Casgevy and Lyfgenia, for treating sickle cell disease (SCD) in patients aged 12 and older. Casgevy, uses technology to modify blood stem cells, increasing fetal hemoglobin to prevent sickling. Lyfgenia, uses a lentiviral vector to produce a hemoglobin that reduces sickling. Both treatments involve collecting patients' stem cells, using chemotherapy to prepare the bone marrow, and re-infusing the modified cells. These approvals are major advances for treating SCD, a disease with limited options (U.S. Food & Drug Administration, 2023).

Pros

jrose11_11 — 2024-05-22 18:09:51 UTC

Potential Cure: Gene therapy aims to correct the genetic defect as opposed to traditional treatment of symptomatic management.
Improve Quality of Life: Gene therapy can decrease or eliminate symptoms associated with crises, thus greatly improving patients' quality of life.
Single Treatment: Gene therapy is given back as a one-time single-dose infusion, as opposed to ongoing treatments and routine medication.
Decreased Transfusion-Associated Risk: When gene therapy is successful the need for regular blood transfusions is decreased or eliminated, therefore lowering transfusion-associated risk.
Personalized Treatment: The patient's genetic makeup is targeted in gene therapy, making each treatment personalized to the individual.

Cons

jrose11_11 — 2024-05-22 18:09:56 UTC

High Cost: Gene therapy treatments are expensive and not all patients in need may be able to afford treatment.
Chemotherapy-associated Risk: Chemotherapy required for stem cell infusions can often have severe side effects.
Long-term Monitoring: Gene therapy is relatively new making the long-term effectiveness and potential late-onset side effects not completely understood, thus requiring lifelong monitoring.
Potential Adverse Reaction: There is a risk of the patients' immune system rejecting the modified genes and this could cause adverse reactions.
Ethical Concern: When genetic alterations are made, ethical issues and concerns may arise.

Rationale

jrose11_11 — 2024-05-22 18:10:13 UTC

Sickle cell disease significantly impacts a large population, causing considerable negative effects. Gene therapy has the potential to revolutionize the treatment and possibly cure hemoglobinopathies like sickle cell disease. The recent innovations, Casgevy and Lyfgenia, could profoundly improve the lives of those affected by the condition. However, the groundbreaking potential of these therapies must be carefully considered and thoroughly evaluated as highlighted in the cons.

Teams

jrose11_11 — 2024-05-22 18:10:31 UTC

My top 5 strengths

Harmony: I will leverage this strength to build consensus in decision-making.
Connectedness: I will use this strength to foster a sense of belonging within the team.
Empathy: Demonstrating this strength will enhance trust, communication, and self-worth among team members.
Adaptability: This strength will nurture a culture of innovation, encouraging team members to take calculated risks and explore new ideas.
Developer: This strength enables me to recognize and cultivate the potential in others, thereby creating a powerful team.

The Team

Alice - Achiever: This strength will inspire others on the team to take action, setting the pace for the workload.

Sheila - Strategic: This team member will help streamline processes, enhance productivity, and promote innovation.

Pablo - Positivity: This team member will create a supportive environment where members are motivated to go above and beyond.

Fernando - Focus: This team member will help the team concentrate on critical tasks and avoid distractions, ensuring deadlines are met.

Carter - Communication: This team member will represent the team effectively, delivering messages clearly and reducing the potential for misunderstandings and conflicts.

References

jrose11_11 — 2024-05-22 18:10:38 UTC

Cleveland Clinic. (n.d.). Gene Therapy for Hemoglobinopathies. [Video]. https://www.youtube.com/watch?v=eSxErZICEXg&t=116s

U.S. Food and Drug Administration. (2023, December 8). FDA approves first gene therapies to treat patients with sickle cell disease. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease